In vivo experiments confirmed that XFPC capsules could significantly express inflammatory factor TNF-α,IL-8,IL-1β in serum of COPD rats, and promote the repair of damaged lung tissue compared with Dexamethasone treatment control group (Xue et al., 2016a; Xue et al., 2016b; Xue et al., 2017). The gene discussed is IL1B; the disease is chronic obstructive pulmonary disease.